Statins After 70 With No Heart Disease: What the STAREE Trial Settled and What It Didn't

There is a small plastic organizer on a lot of kitchen counters, seven compartments, one letter for each day. Somewhere in it sits a statin that someone started in their fifties, or sixties, or last spring because a number on a lab report crossed a line. And somewhere else, a person turning seventy is wondering whether to start one at all.

For years the honest answer for that second person was: nobody really knows. Most of the big statin trials were built around middle-aged adults, and the evidence for people past seventy who have never had a heart attack or stroke was thin. A trial called STAREE was designed to fill exactly that gap. It reported in late August 2026, and the result is the kind that refuses to hand you a slogan.

What STAREE Actually Tested

STAREE, led by Sophia Zoungas and colleagues at Monash University in Australia and published in the New England Journal of Medicine, enrolled 9,971 people aged 70 or older. They were living in the community, recruited through general practices, and they had no known cardiovascular disease, no diabetes and no dementia. In other words, relatively well older adults, the group where the question is truly open.

Half were assigned to atorvastatin 40 mg a day and half to a placebo, with neither participants nor doctors knowing which was which. They were followed for a median of about six years, which is long enough to see real events and short enough that the participants were still living the same life they started with.

Two outcomes mattered. The first was major cardiovascular events, the heart attack and stroke kind. The second was a composite that asked a broader question: did people live longer without dementia and without persistent physical disability?

What It Found

On the first outcome, the statin worked. Major cardiovascular events occurred in about 6.0% of the atorvastatin group and 8.3% of the placebo group, a relative reduction of roughly 30%.

On the second outcome, it did not. The composite of death, dementia or persistent disability was not significantly different between the two groups. Muscle, liver and diabetes-related adverse events were more common on the drug, although serious adverse events overall were about equal in both arms.

So the same trial says "it helped" and "it did not change the thing you might care about most." Both statements are accurate. The work is in holding them together.

Reading "Fewer Heart Events, No Change in Disability-Free Survival"

Start with the size of the benefit. A 30% relative reduction sounds large, and it is a fair summary of the effect. The absolute difference is the gap between 8.3% and 6.0%, about 2.3 percentage points over roughly six years. Put differently, around 43 people would need to take the pill for six years for one of them to avoid a major cardiovascular event. Some of those 43 would have had no event anyway, and most of them would feel nothing either way. A benefit you will never feel is a strange thing to commit to every morning, though plenty of good medicine works exactly like that.

Then look at why the broader outcome stayed flat. It bundles together death from any cause, dementia and lasting disability. In a group whose average age was in the mid-seventies, most of those events have little to do with arteries. The trial authors noted that the large majority of deaths were from non-cardiovascular causes. A drug that trims one slice of the risk can only move a composite built from many slices by a small amount, and a trial of this size may not be able to detect it.

That is the part worth sitting with: "no significant change" is not the same as "proved no effect." It means this trial could not show one on this outcome. Absence of a signal and evidence of absence are neighbors that people constantly mistake for each other.

What the result does not say is that statins are useless after seventy, and it does not say they are a bargain. It says the benefit is real, moderate and specific to heart events, and that it arrives with a modest cost in side effects for some people.

Deciding Whether to Start or Stop

If you are not on a statin, the question is whether a roughly two-in-a-hundred absolute reduction in heart events over six years is worth a daily pill, a possible muscle ache, and a small bump in blood sugar. For someone with a family history of early heart disease, high blood pressure, or a coronary calcium score that came back high, the baseline risk is above the average in this trial, so the same relative benefit buys more. For someone with low baseline risk, or who is frail, or who has a limited life expectancy for other reasons, the arithmetic tilts the other way.

If you are already on one and tolerating it, STAREE gives no reason to panic or to stop on your own. The trial tested starting, not stopping. Those are different questions, and stopping carries its own uncertainty.

That second question is being studied separately. A statin-discontinuation trial called STREAM is scheduled for presentation at the American Heart Association's 2026 meeting, so check whether it has reported before assuming the answer. Until then, "should I stop at 78?" is a conversation with your clinician, not a headline.

One more caution that applies to everyone: this trial excluded people with existing cardiovascular disease and diabetes. If you have either, STAREE is not about you, and the case for a statin is much stronger and has decades of other evidence behind it.

What It Didn't Settle

It did not settle how the benefit varies by age within the group. Someone who is 71 and someone who is 84 are both "over 70," and they are not the same patient. It did not settle whether people who value independence above all should weigh the neutral disability result more heavily than the heart result. It did not settle how much a mild but real muscle ache matters when it costs someone their daily walk, which is its own health risk.

These are questions of values rather than data. Two sensible people can look at identical numbers and choose differently, and both can be right. I find that oddly freeing. The trial does not remove the decision. It makes the decision honest.

A Shared-Decision Worksheet for Statins After 70

Bring this to an appointment, or fill it in at the kitchen table first. It is a thinking tool, not medical advice.

1. My starting point. Have I had a heart attack, stroke, stent or bypass? Do I have diabetes or dementia? If yes to any, STAREE does not apply and this worksheet is the wrong tool. Ask about it directly.
2. My risk picture. Blood pressure, LDL cholesterol, smoking history, family history of early heart disease, any coronary calcium score. Ask the clinician to estimate my ten-year risk and to tell me which number they used.
3. What a statin could do for me. Ask: "Out of 100 people like me, how many avoid a heart attack or stroke over six years?" Write down the answer, in absolute terms.
4. What it could cost me. Muscle aches, liver blood tests, a small rise in blood sugar, pill burden, money. Which of these would bother me most?
5. What I care about most. Avoiding a heart attack or stroke? Staying independent as long as possible? Not adding another daily medication? Rank these.
6. If I am already on a statin. Am I tolerating it? Has anything changed in my health or goals? Is stopping something to discuss, and what would we watch for if we tried?
7. The plan. Start, continue, stop, or decide later with a date to revisit. Write the date down.

A good appointment ends with both of you able to say, in one sentence, why you chose what you chose.

FAQ

Should I stop my statin because of this trial?

No, not on your own. STAREE tested people starting a statin, not stopping one. If you are on a statin and feel fine, the sensible step is to raise it at your next visit and ask whether your situation has changed.

Does "no change in disability-free survival" mean statins do nothing?

It means this trial could not show a difference on that broader outcome. The heart-event benefit was clear. A broader composite is harder to move, and a trial can miss a small effect.

Does this apply if I have diabetes or have already had a heart attack?

No. The trial excluded people with cardiovascular disease, diabetes and dementia. For people who have had a heart attack or stroke, statins are well established and the evidence is much older and stronger.

Are the side effects serious?

Muscle, liver and diabetes-related events were more common on the drug, but serious adverse events overall were about equal between the groups. For many people the main practical issue is muscle discomfort, which can often be managed by changing the dose or the drug.